VEGFA and retinopathy of prematurity: Given that the administration of anti-VEGFs in ROP has led to fewer ocular biometric alterations compared to earlier treatment methods (such as laser and cryotherapy), the ultimate refractive outcomes for these patients have also differed.[2] Thus, eyes treated with anti-VEGF agents have exhibited a lower degree of myopia.